Sub menu

 
 

Australian Public Assessment Reports (AusPAR)

Search our AusPAR dataset.

An AusPAR provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve an application.

For more information see Australian Public Assessment Reports for prescription medicines (AusPARs).

Use the filters below to narrow your search.

Filter results

You can narrow down the results using the filters.

Sponsor

Topics

AusPAR Date

1062 result(s) found, displaying 176 to 200

  • AusPAR: Spikevax

    Australian Public Assessment Report (AusPAR)
    Spikevax (elasomeran) for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older

  • AusPAR: Tivicay and Tivicay PD

    Australian Public Assessment Report (AusPAR)
    TIVICAY (dolutegravir ) for treatment of HIV infection in combination with other antiretroviral agents.

  • AusPAR: Nuvaxovid

    Australian Public Assessment Report (AusPAR)
    Nuvaxovid (SARS-CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for prevention of COVID-19 in individuals 12 years of age and older.

  • AusPAR: Crysvita

    Australian Public Assessment Report (AusPAR)
    Crysvita (burosumab) for the treatment of X-linked hypophosphataemia (XLH)

  • AusPAR: Verquvo

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Verquvo (vericiguat) as addition to standard of care therapy for the treatment of symptomatic chronic heart failure.

  • AusPAR: VeraSeal

    Australian Public Assessment Report (AusPAR)
    VeraSeal (human fibrinogen and human thrombin) for the supportive treatment of hemostasis.

  • AusPAR: Trastuzumab deruxtecan

    Australian Public Assessment Report (AusPAR)
    Enhertu (trastuzumab deruxtecan) for treatment of unresectable or metastatic HER2 positive breast cancer.

  • AusPAR: Nuvaxovid homologous booster

    Australian Public Assessment Report (AusPAR)
    Nuvaxovid homologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.

  • AusPAR: Nuvaxovid heterologous booster

    Australian Public Assessment Report (AusPAR)
    Nuvaxovid heterologous booster (CoV-2 rS with Matrix M adjuvant (NVX-CoV2373)) for the prevention of COVID-19.

  • AusPAR: Bevacizumab

    Australian Public Assessment Report (AusPAR)
    Bevacip/Bevaciptin (bevacizumab) for the treatment of types of cancer.

  • AusPAR: Finerenone

    Australian Public Assessment Report (AusPAR)
    Kerendia (finerenone) for the treatment of progressive decline of kidney function in adults.

  • AusPAR: Deutetrabenazine

    Australian Public Assessment Report (AusPAR)
    AUSTEDO (deutetrabenazine) for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adult.

  • AusPAR: Remdesivir

    Australian Public Assessment Report (AusPAR)
    New AusPAR for VEKLURY (remdesivir ) for the treatment of coronavirus disease 2019 in paediatric and adult patients.

  • AusPAR: Belumosudil

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Rholistiq (belumosudil) for the treatment of patients with chronic graft-versus-host disease aged 12 years and older.

  • AusPAR: Dupilumab

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Dupixent (dupilumab) for the treatment of atopic dermatitis and chronic rhinosinusitis with nasal polyposis.

  • AusPAR: Lurbinectedin

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Lurbinectedin

  • AusPAR: Luspatercept

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Luspatercept

  • AusPAR: Venetoclax

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Venclexta (venetoclax) for acute myeloid leukaemia indication, provisional to full registration.

  • AusPAR: Inclisiran

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Inclisiran

  • AusPAR: Amifampridine

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Ruzurgi (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome.

  • AusPAR: Tozinameran

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Tozinameran

  • AusPAR: Forxiga

    Australian Public Assessment Report (AusPAR)
    Forxiga (dapagliflozin) has been approved for reducing the risk of progressive decline in kidney function in adults with
    proteinuric chronic kidney disease.

  • AusPAR: Sacituzumab govitecan

    Australian Public Assessment Report (AusPAR)
    New AusPAR for Trodelvy (sacituzumab govitecan) for the treatment of breast cancer.

Help us improve the Therapeutic Goods Administration site